HHS Part B Plan Gets Pharma's Attention, But Savings Target May Be Too High
Executive Summary
Regeneron analysis of policy's potential impact on Eylea signals that MA plans will face overwhelming challenge to achieve 20% savings in Part B.
You may also be interested in...
Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
The Greatest FDA Advisory Committees Of All Time Part IV: Neurology Lays Claim To The Crown
We look back at another of the greatest FDA advisory committees of the last 20 years. This time: the nearly 12-hour meeting in 2016 on Sarepta’s eteplirsen for Duchenne muscular dystrophy.
Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.